|Bid||0.4656 x 1000|
|Ask||0.4662 x 2200|
|Day's Range||0.4501 - 0.4912|
|52 Week Range||0.3700 - 5.0000|
|Beta (3Y Monthly)||2.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...
The Richmond, British Columbia-based company said it had a loss of 70 cents per share. Losses, adjusted for amortization costs and non-recurring costs, were 61 cents per share. The medical device company ...
Neovasc Inc. - Common Shares (NASDAQ: NVCN ) announces its next round of earnings this Wednesday, Nov. 14. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement. Earnings and ...
Neovasc said its Tiara transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting held in Milan, Italy. Tiara is being developed by Neovasc for treating mitral regurgitation, a condition affecting about 4 million patients in the U.S.
Neovasc stock (NASDAQ:NVCN) is skyrocketing more than 26% on Wednesday as the company received good news from the U.S. Food and Drug Administration (FDA) regarding one of its latest products. The medical device company revealed that its Neovasc Reducer device that was designed to treat refractory angina was granted a Breakthrough Device designation by the FDA. The news caused Neovasc stock to skyrocket with volume soaring up to 21.2 million shares, which is considerably higher than the stock’s full-day average of just under 800,000 shares.
The Richmond, British Columbia-based company said it had a loss of 4 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, were less than 1 cent on a per-share basis. The ...
In this article, I’m going to take a look at Neovasc Inc’s (TSE:NVCN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
Neovasc Inc (NASDAQ: NVCN), a specialty medical device company that develops, manufactures and markets products for the cardiovascular segment of the healthcare market is witnessing great traction this week. The company has just announced its first patient implant using its flagship medical device, NVCN reducer. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock.
Neovasc Inc’s (NASDAQ:NVCN): Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. The company’s loss has recently broadened since it announced a -US$22.91M loss inRead More...